Antitumor activity of T cells expressing a novel anti-FOLR1 CoStAR in a human xenograft murine solid tumor model and implications for in-human studies Post date June 10, 2022 ← Characterization of the Transcriptomic and T-Cell Receptor (TCR) Clonal Heterogeneity of Tumor-Infiltrating Lymphocyte (TIL) Therapy Infusion Products by Single-Cell Sequencing and Correlative Analyses With Clinical Efficacy in Patients With Advanced Cutaneous Melanoma (ASGCT) → Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma
Instil BioInstil Bio